[6929] Yejuyi Medical Plans Regular Interim Dividend Distribution; China Market Revenue Declined Nearly 14% Last Year Due to Volume-Based Procurement Impact

SocialAnxietyStaker · 2026-03-13T10:08:07+00:00

Mediwound Ltd. announced an increase in final dividend of 20% to 12 cents, with total annual dividend of 27 cents. The Chief Operating Officer indicated that regular interim dividends may be paid in the future. Despite sales revenue from the Chinese market declining by nearly 14% due to centralized procurement effects, the company plans to deepen its presence in the Chinese market and anticipates growth. Additionally, the new manufacturing facility in Hangzhou Fuyang is expected to commence production in 2027 and will become the primary research and development production base.

SocialAnxietyStaker

2026-03-13 10:08:07

Abstract generation in progress

Medical device company Yejuyu Medical (06929), headquartered in Science Park, increased its final dividend by 20% to 12 cents, including a special dividend declared during the mid-year results to mark its 25th anniversary. The total annual dividend is 27 cents. Yejuyu Medical Chief Operating Officer Liu Guizhen stated that the special dividend received positive shareholder feedback and that the company may maintain regular mid-year dividends in the future. With ample funds and positive operating cash flow, the company hopes to reward shareholders when possible. CFO Chen Yongcheng added that no fixed dividend payout ratio has been set and future dividends will be based on actual business conditions.

China Market Sales Revenue Drops Nearly 14% Due to Collective Procurement Impact

Yejuyu Medical mainly develops and sells medical devices such as balloons and stents used in “Tongbozai” procedures. Its products are sold in over 70 countries and regions worldwide. However, last year, sales revenue in the Chinese market fell nearly 14%.

Liu Guizhen explained that last year the company entered collective procurement for the first time, which put some pressure on profit margins. However, the new round of collective procurement features more moderate prices. Additionally, after joining the procurement, more products entered hospital markets, which is believed to still drive revenue growth. The company also plans to continue deepening its presence in the Chinese market.

New Factory in Fuyang, Hangzhou Expected to Start Production in 2027

CFO Chen Yongcheng stated that Yejuyu Medical’s new factory in Fuyang, Hangzhou, has been topped out and is expected to start production in 2027. The project has a total investment of approximately 430 million RMB. Once completed, it will become the company’s largest R&D and manufacturing base.

As of the end of last year, about 58% of Yejuyu’s revenue came from direct sales, with the remainder from distribution channels. Management indicated that the company has over $200 million in net cash, recently acquired a distribution network in Indonesia, and is interested in acquiring European sales channel companies and merging with firms that own products or technologies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.